Gunnar Kaufmann - Oncternal Therapeutics Chief Officer

Insider

Gunnar Kaufmann is Chief Officer of Oncternal Therapeutics
Age 48
Phone858 434 1113
Webhttps://www.oncternal.com

Oncternal Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.7645) % which means that it has lost $0.7645 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4986) %, meaning that it created substantial loss on money invested by shareholders. Oncternal Therapeutics' management efficiency ratios could be used to measure how well Oncternal Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Oncternal Therapeutics currently holds 318 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Oncternal Therapeutics has a current ratio of 10.56, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Oncternal Therapeutics' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

AO FRACPAssembly Biosciences
65
Desiree DDSPassage Bio
N/A
Sean McClainAbsci Corp
35
Erin ButlerArmata Pharmaceuticals
N/A
MS JDSurrozen
62
CPA CPAAbsci Corp
65
Christopher OgdenCytomX Therapeutics
41
Duane BAArmata Pharmaceuticals
74
Brigit RileyAdverum Biotechnologies
46
Oleg NodelmanNuvation Bio
44
Andreas BuschAbsci Corp
62
W VernonNuvation Bio
65
Daniel SchneidermanPasithea Therapeutics Corp
47
Christopher GarciaSurrozen
N/A
Wenyuan ShiArmata Pharmaceuticals
N/A
Daniel WelchNuvation Bio
63
Simona KingPassage Bio
52
Yassine BendiabdallahPasithea Therapeutics Corp
41
Kim BlickenstaffNuvation Bio
68
Uri MDAssembly Biosciences
53
MBA MDSurrozen
56
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. Oncternal Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people. Oncternal Therapeutics (ONCT) is traded on NASDAQ Exchange in USA. It is located in 12230 El Camino Real, San Diego, CA, United States, 92130 and employs 27 people. Oncternal Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.

Management Performance

Oncternal Therapeutics Leadership Team

Elected by the shareholders, the Oncternal Therapeutics' board of directors comprises two types of representatives: Oncternal Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oncternal. The board's role is to monitor Oncternal Therapeutics' management team and ensure that shareholders' interests are well served. Oncternal Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oncternal Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Pablo Urbaneja, Senior Development
Anita Wiseth, Senior Resources
Gunnar Kaufmann, Chief Officer
Chase JD, General Secretary
Salim MD, Chief Officer
Chase Leavitt, General Secretary
Steven Hamburger, VP Assurance
Richard CPA, Treasurer CFO
Rajesh Krishnan, Chief Officer

Oncternal Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Oncternal Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Other Consideration for investing in Oncternal Stock

If you are still planning to invest in Oncternal Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oncternal Therapeutics' history and understand the potential risks before investing.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Bonds Directory
Find actively traded corporate debentures issued by US companies
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes